David Neafus

Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA.

Link Medicine Corp. develops disease modifying neurodegenerative therapies. The company was founded by Edward I. Rudman, Peter T. Lansbury, David Neafus and Adam J. Rosenberg in 2005 and is headquartered in Cambridge, MA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH.

KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY.